We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Pro Medicus is a health information services business based in Australia. Pro Medicus shares (PME) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollar. Pro Medicus has a trailing 12-month revenue of around $67.9 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Long-term investing
| 52-week range | $37.8906 - $69.9044 |
|---|---|
| 50-day moving average | $57.5504 |
| 200-day moving average | $54.93 |
| Target price | $57.9 |
| PE ratio | 153.8305 |
| Dividend yield | $0.15 (0.35%) |
| Earnings per share (TTM) | $0.295 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$41.78
| 1 week (2022-01-21) | -7.93% |
|---|---|
| 1 month (2021-12-24) | -31.51% |
| 3 months (2021-10-28) | -23.55% |
| 6 months (2021-07-28) | -25.70% |
| 1 year (2021-01-28) | 1.41% |
|---|---|
| 2 years (2020-01-28) | 63.46% |
| 3 years (2019-01-25) | 230.28% |
| 5 years (2017-01-27) | 716.02% |
Valuing Pro Medicus stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pro Medicus's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Pro Medicus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 154x. In other words, Pro Medicus shares trade at around 154x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Pro Medicus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $42.6 million (£0.0 million).
The EBITDA is a measure of a Pro Medicus's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $67.9 million |
|---|---|
| Operating margin TTM | 62.43% |
| Gross profit TTM | $67.4 million |
| Return on assets TTM | 23.95% |
| Return on equity TTM | 43.49% |
| Profit margin | 45.45% |
| Book value | 0.784 |
| Market capitalisation | $4.7 billion |
TTM: trailing 12 months
Dividend payout ratio: 50% of net profits
Recently Pro Medicus has paid out, on average, around 50% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.35% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Pro Medicus shareholders could enjoy a 0.35% return on their shares, in the form of dividend payments. In Pro Medicus's case, that would currently equate to about A$0.15 per share.
Pro Medicus's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
The latest dividend was paid out to all shareholders who bought their shares by 8 September 2021 (the "ex-dividend date").
Over the last 12 months, Pro Medicus's shares have ranged in value from as little as $37.8906 up to $69.9044. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Pro Medicus's is 0.2277. This would suggest that Pro Medicus's shares are less volatile than average (for this exchange).
Pro Medicus Limited develops and supplies healthcare imaging software and services to hospitals, diagnostic imaging groups, and other related health entities in Australia, North America, and Europe. It provides Radiology Information Systems (RIS) proprietary medical software for practice management. The company also offers Healthcare imaging software that provides radiologists and clinicians with visualization capability for viewing 2-D, 3-D, and 4-D medical images, as well as picture archive and communication system (PACS)/digital imaging software; Promedicus.net., an e-health platform; and integration products. In addition, it offers Visage Ease Pro, a mobile application, which allow users to interpret medical imaging studies that are stored on a Visage 7 server; training, installation, and professional services; and after sale support and service products. The company provides its products under the Visage RIS, Visage RIS/PACS, Visage 7, and Visage Ease names. Pro Medicus Limited was incorporated in 1983 and is headquartered in Richmond, Australia.
In an exclusive interview with Finder, VP of Strategic Innovations Lab, Nicolas Pouard, spells out he future of Ubisoft's NFTs
BMW Australia's 8 Series range is set to receive an update for the 2022 model year with slightly refreshed styling and additional tech headlining the updates for its flagship luxury sports model.
The current market sell-off is providing an opportunity for investors to pick up structural winners at a discount, two industry experts say.
Recovering from trauma is a lengthy process.
We talk to Nicolas Pouard, VP at Ubisoft's Strategic Innovations Lab, about the launch of Ubisoft Quartz and the Digits NFTs
Westpac predicts 6 mortgage rate rises before Christmas 2023. If they’re on the money, how much would this cost mortgage-holders?
On your marks, get set, bake!
Hotel quarantine could cost you thousands unless you get the right travel insurance policy.
Your credit limits can affect your credit score and your chance of approval, but it's not always as simple as changing one to improve the other.
